stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
124.40
19.26
−13.41%
Follow GRAL
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
39.34 | 17.81 | 13.45 | 21.37 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(87.70) | (36.46) | (24.14) | (49.32) | |
P/B ratio |
2.67 | 1.16 | 0.84 | 1.22 | |
Price to Tangible BV |
9.27 | 3.87 | 3.07 | 4.33 | |
EV/Sales |
34.17 | 12.60 | 8.18 | 15.23 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.59) | (7.06) | (4.39) | (7.50) | |
EV/FCF |
(18.25) | (7.03) | (4.37) | (7.47) | |
Quick Ratio |
0.20 | 10.55 | 11.29 | 11.58 | |
Current Ratio |
8.93 | 10.95 | 11.74 | 11.97 | |
Net Debt/EBITDA |
— | 7.44 | 7.95 | 10.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.06 | 0.06 | 0.05 | |
Operating CF/Net income |
0.72 | 0.73 | 0.93 | 0.64 | |
Capex/Depreciation |
0.00 | (0.01) | (0.02) | 0.00 | |
Research and Development Expense of Revenue |
117.42% | 106.14% | 117.74% | 107.57% | |
Selling, General and Administrative Expense of Revenue |
219.62% | 197.74% | 180.06% | 152.26% | |
Intangible Assets out of Total Assets |
0.64 | 0.63 | 0.65 | 0.63 | |
Share Based Compensation of Revenue |
37.59% | 43.76% | 41.17% | 31.57% | |
Graham Net Nets |
0.09 | 0.21 | 0.27 | 0.19 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.78%) | (14.28%) | (20.07%) | (13.06%) | |
Free Cash Flow Yield |
(4.76%) | (10.06%) | (13.92%) | (9.53%) | |
Revenue per Share |
0.80 | 1.04 | 1.00 | 1.19 | |
Operating CF per Share |
(1.60) | (1.87) | (2.14) | (1.74) | |
Capex per Share |
(0.10) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.70) | (1.88) | (2.15) | (1.74) | |
Cash per Share |
0.00 | 19.98 | 20.25 | 24.61 | |
Shareholders Equity per Share |
52.45 | 58.98 | 61.53 | 70.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
52.45 | 58.98 | 61.53 | 70.14 | |
Free Cash Flow |
(79.47) | (81.16) | (87.49) | (63.88) | |
Working Capital |
748.47 | 831.18 | 802.64 | 874.18 | |
Capital Expenditures |
(4.73) | (0.43) | (0.50) | (0.09) | |
Net Current Asset Value |
565.76 | 613.69 | 574.56 | 609.70 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.13 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.64 | 18.04 | 19.83 | 19.30 | |
Average Payables |
6.81 | 6.76 | 5.22 | 3.46 | |
Average Assets |
2,665.80 | 2,773.12 | 2,825.54 | 2,952.66 | |
Average Common Equity |
2,346.74 | 2,428.65 | 2,457.18 | 2,540.63 |
Columns are period end dates · fundamentals updated 5 Nov 2026